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E-mail: ferbarmd@yahoo.comCase ReportA 67-year-old African American woman with a medical history of
obesity (body mass index 38 kg/m2), chronic active smoker,
chronic obstructive pulmonary disease, obstructive sleep apnea
receiving continuous positive airway pressure therapy, severe
pulmonary hypertension, atrial ﬁbrillation on anticoagulation,
well-controlled type 2 diabetes, hypertension and dyslipidemia,
who had been discharged to a rehabilitation facility from our
institution 4 weeks before after being treated for hypercapnic
hypoxic respiratory failure requiring mechanical ventilation,
presented with sudden-onset generalized weakness, light-
headedness, shortness of breath and dry cough after waking up
the morning of admission. One day before admission, the patient
was discharged from a rehabilitation center where she received
physical therapy/hydrotherapy sessions. The patient was in
distress but denied subjective fevers, chills, headache, photo-
phobia, sputum production, nausea, vomiting, diarrhea, dysuria,
vaginal discharge, recent travel or exposure to pets. Patient’sNew Microbes and New Infections © 2015 The Authors. Published by El
This is an open access artimedications included: simvastatin, metformin, glipizide, valsartan,
labetalol, diltiazem,warfarin, ﬂuticasone/salmeterol and albuterol.
Physical examination revealed hypotension (64/36 mm Hg)
which required epinephrine drip, tachypnea of 32 breaths/min,
O2 saturation of 78% on 2 liters per nasal cannula (91% on
biphasic positive airway pressure), pulse 110/min and tempera-
ture of 98.9°F (37.2°C).
The patient was alert and oriented to person, place and time,
was in distress and showed conjunctival pallor, dry mucous
membranes, arrhythmic heart sounds with a 2/6 pansystolic
tricuspid murmur, lungs with bilateral crackles at bases and
wheezing, nontender abdomen with ascetic wave and 2+ edema
in lower extremities with decreased peripheral pulses, but no
evidence of skin ulcers. Neurologic examination did not reveal
meningeal signs or focal deﬁcits.
Empiric therapy of cefepime and vancomycin was initiated.
Laboratory results showed a leukocyte count of 15.6
cells/mL, neutrophils 85%, no bandemia and platelets
877000/mL. Patient also presented with acute kidney injury
with a creatinine of 1.3 mg/dL (baseline 0.6 mg/dL) and hy-
perglycemia 183 mg/dL. Lactate level was 3 mmol/L. Interna-
tional normalized ratio was 3. HIV test was negative. Urinalysis
was negative for blood, nitrates and leukocyte esterase; it had 5
to 10 white blood cells and many bacteria.
Chest and abdominal computed tomography revealed a
previously identiﬁed right pleural effusion with associated right-New Microbe and New Infect 2015; 7: 33–36
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FIG. 1. Sphingobacterium multivorum blood culture susceptibility testing
results.
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caliber hepatic veins.
Transesophageal echocardiogram showed an ejection frac-
tion of 60%, severe pulmonary hypertension, severe tricuspid
regurgitation, mild mitral regurgitation and no signs of endo-
carditis. Cytology of peritoneal and the exudative pleural ﬂuid
was negative for malignant cells. Blood, urine, pleural and
peritoneal ﬂuid samples were sent for culture.
On the second day of hospitalization, the patient no longer
required vasopressors. Two sets of blood samples were drawn
for culture, and the two sets identiﬁed Gram-negative bacilli.
Vancomycin was discontinued. On the fourth day of hospitali-
zation, the ﬁnal identiﬁcation of blood cultures showed Sphin-
gobacterium multivorum resistant to ceftazidime and
trimethoprim/sulfamethoxazole (TMP/SMX) and with interme-
diate susceptibility to meropenem and piperacillin/tazobactam
(Fig. 1). The method used for identiﬁcation involved using
MacConkey agar, a breakpoint panel with biochemical and
sensitivity sections for identiﬁcation and susceptibility tests,
respectively, and a MicroScan WalkAway Plus-40 Microbiology
System. Cefepime was switched to ciproﬂoxacin. Gram stain of
urine was not reported, but urine culture came negative, as did
peritoneal and pleural ﬂuid cultures. The patient was clinically
stable to be discharged with a total of 10 days of ciproﬂoxacin.
Repeated blood and urine cultures taken 5 days after admission
were negative. Patient was followed up 2 and 4 weeks after
discharge and was clinically stable.DiscussionBacteria that belong to the genus Sphingobacterium are Gram-
negative, non-lactose-fermentative microorganisms that are
positive for catalase and oxidase tests and produce small,New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licecircular, convex, smooth and opaque colonies with light yellow
pigment when incubated at 35°C in either carbon dioxide or
ambient air for a minimum of 24 hours. Growth on MacConkey
agar is usually detectable within 24 hours of inoculation [1]. An
important feature of bacteria that belong to this genus is the
presence of high concentrations of sphingophospholipids in
their cell membrane [2].
These microorganisms are ubiquitous in nature but are
rarely involved in human infections. Sphingobacterium can be
found in soil, on plants, in foodstuffs and in water sources [3].
Sphingobacterium species have the ability to survive in moist
hospital environments; these organisms thus also have the po-
tential to contaminate laboratory culture media and blood
culture systems. Whenever these species are encountered,
their clinical signiﬁcance and the potential for contamination
should be seriously considered [1].
The few reported cases of infections resulting from
S. multivorum usually occurred in severely comorbid patients
(Table 1), causing, for instance, necrotizing fasciitis and septic
shock in a patient with rheumatoid arthritis treated with long-
term intermediate-dose corticosteroids (0.25 mg/kg of predni-
sone per day for more than 30 years) [3], bacteraemia in immu-
nocompromised hosts [4–6], sepsis in the setting of bacteraemia
in a hemodialyzed patient [7], peritonitis [8], chronic respiratory
tract infection in patients with cystic ﬁbrosis [9,10] (where,
however, it was not associated with a deterioration of pulmonary
function during the follow-up period [10]) and respiratory infec-
tion in a patient with chronic obstructive pulmonary disease [11].
In addition, the medical literature mentions a report of three
cases of cystitis, one of which was complicated with bacter-
aemia, within a period of 10 days after transrectal ultrasound-
guided prostate biopsy where an infection hygiene evaluation
identiﬁed and changed a step in the biopsy process in order to
reduce the risk of inocula [12].
Although we could not establish the source of the pathogen,
we speculate that it was present in the water or soil of the
rehabilitation facility.
Sphingobacterium species are intrinsically resistant to many
commonly used antibiotics and can grow in antiseptics and
disinfectants [2,13]. S. multivorum can produce an extended-
spectrum β-lactamase and a metallo-β-lactamase, conferring
resistance to third-generation cephalosporins and carbape-
nems, respectively [14]. In our review of the literature, the
three most common susceptible antibiotic therapies were TMP/
SMX, quinolones and tetracycline; however, in our case, there
was resistance to TMP/SMX.
Including our case, we found a total of 14 cases of
S. multivorum infection in nine male and ﬁve female subjects. Of
the 11 cases where age was reported, ten occurred in adults;
mean age was 56 years. One of the 14 patients died.European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 33–36
nses/by-nc-nd/4.0/)
TABLE 1. Summary of Sphingobacterium multivorum reports
Study Patient characteristics Comorbidities Diagnosis Susceptibility testing results Treatment and outcome
Dhawan [8] 60-year-old man with nausea, vomiting and
vague abdominal discomfort for 2 weeks
Alcoholic liver disease, esophageal stricture
due to prior suicide attempt by ingesting
liquid Drano (a strong alkaline corrosive)
Sepsis due to spontaneous bacterial
peritonitis; hospital course complicated
with aspiration pneumonia causing acute
respiratory failure
Resistant to ampicillin, amikacin, gentamicin,
chloramphenicol and cephalosporins;
susceptible to tetracycline, carbenicillin,
TMP/SMX
Initially treated with ampicillin and
gentamicin for 5 days with no
improvement, then treated with
gentamicin and carbenicillin for 11 days.
Full recovery. LOS: 21 days
Potvliege [7] 43-year-old man with chills, fever and
myalgias for 1 day
Chronic renal insufﬁciency on hemodialysis
through arteriovenous ﬁstula, bilateral
nephrectomy; history of infected
arteriovenous ﬁstula
Bacteraemia Resistant to penicillins, cephalosporins,
tobramycin, amikacin, colistin; susceptible
to erythromycin, tetracycline,
chloramphenicol, vancomycin,
gentamicin, sulfonamides, TMP/SMX
Treated with ampicillin (MIC of 8 μg/mL)
for 10 days and 1 dose of tobramycin. Full
recovery. LOS: no data
Freney [4] 57-year-old man with fever 5 days after
starting chemotherapy
Immunoblastic type non-Hodgkin
lymphoma treated with chemotherapy
complicated by development of bone
marrow aplasia
Sepsis in setting of bacteraemia MICs (mg/L): peﬂoxacin, 0.5; rifampin, 1;
tetracycline, 2; erythromycin, 4; TMP/
SMX, 5; chloramphenicol and
ceftriaxone, 8; ceftazidime and
cefotaxime, 16; carbenicillin and azlocillin,
64; piperacillin and cephalotin, 128;
gentamicin, tobramycin, vancomycin,
>16; ampicillin, aztreonam and amikacin,
>32; fosfomycin, >128
Treated with a combination of peﬂoxacin
and TMP/SMX. Full recovery. LOS: no
data
Reina [10] 20-month-old girl diagnosed with cystic
ﬁbrosis at 6 months with fever, cough
productive of abundant mucous and
respiratory difﬁculty for 2 days
Cystic ﬁbrosis Sepsis in setting of acute exacerbation of
chronic bronchopathy
Resistant to aztreonam, gentamicin and
TMP/SMX; susceptible to carbenicillin,
ceftazidime, ceftriaxone, cefuroxime,
chloramphenicol, azlocillin, cefotaxime,
ticarcillin, ciproﬂoxacin, imipenem,
piperacillin, amikacin
Treated with ceftazidime and amikacin. Full
recovery. LOS: no data
Areekul [6] 47-year-old man with fever and chills for 3
months and 10 kg weight loss for 1
month; positive HIV test; cultures from
blood and sputum yielded S. multivorum.
Patient developed meningitis with
negative CSF cultures
Type 2 diabetes; newly diagnosed HIV Bacteraemia, meningitis, liver failure Resistant to ampicillin, gentamycin,
amikacin, carbenicillin; sensitive to TMP/
SMX, chloramphenicol, tetracycline,
cefotaxime, ceftazidime, ceftriaxone
Treated initially with gentamycin and
ampicillin. Then switched to ceftriaxone
and TMP/SMX. Patient died on day 6 of
hospitalization
Vella [11] 74-year-old man with 4 days’ history of
chills, subjective fevers, cough productive
of purulent sputum, chest pain; fever,
tachypnea, neutrophilia
COPD, history of several hospitalizations
due to bronchial infections with
Pseudomonas sp.
Sepsis resulting from respiratory infection
(authors did specify if pneumonia was
present)
Resistant to ceftazidime and aztreonam;
intermediate to tobramycin, ticarcillin;
susceptible to TMP/SMX, tetracyclines,
quinolones, aminoglycosides, β-lactams
Treated initially with ceftazidime and then
switched to cefuroxime. Full recovery.
LOS: no data
Lambiase [9] Sputum samples obtained from January
2006 to June 2008 from 332 cystic
ﬁbrosis patients. S. multivorum was
isolated from 3 (2 female, 1 male)
patients; 1 was identiﬁed as chronically
infected by S. multivorum. All patients
coinfected by at least 1 other Gram-
negative pathogen
Cystic ﬁbrosis, pancreatic insufﬁciency Chronic lung infection Resistant to β-lactams, carbapenems,
aminoglycosides; susceptible to TMP/
SMX and quinolones
Authors do not specify which therapy was
used but mentioned that no subsequent
decline in lung function was registered.
LOS: no data
Grimaldi [3] 64-year-old woman with leg pain and fever
24 hours after her dog scratched her
right leg; patient confused, skin mottled
from legs to abdominal wall, right leg was
erythematous, edematous and tender to
palpation
Morbid obesity (BMI 33.5 kg/m2), coronary
artery disease, type 2 diabetes,
rheumatoid arthritis treated with long-
term intermediate-dose corticosteroids
Septic shock, encephalopathy, acute kidney
injury requiring hemodialysis, respiratory
failure in setting of necrotizing fasciitis
Resistance to penicillins, cephalosporins,
carbapenems, aminoglycosides;
susceptible to amoxicillin-clavulanate,
ticarcillin-clavulanate, quinolones, TMP/
SMX
Treated with amoxicillin-clavulanate for 10
days; patient discharged to rehabilitation
unit after 7 weeks; no physical sequelae
Nielsen [12] Report of 3 cases of infections after TRUS-
Bx. All received oral prophylaxis with
pivmecillinam and amoxicillin/clavulanic
acid the night before and 2 hours before
TRUS-Bx. Case 1: 79-year-old man
hospitalized with fever, chills, malaise 3
days after TRUS-Bx; case 2: 59-year-old
man with dysuria and frequent voiding 2
weeks after TRUS-Bx; case 3: 69-year-
old-man followed in active surveillance
program for low-risk prostate cancer
consulted the emergency room 3 days
after TRUS-Bx with dysuria and
hematuria
Case 1: end-stage renal disease resulting
from glomerulonephritis on hemodialysis,
benign prostatic hyperplasia, prostate
cancer; case 2: benign prostatic
hyperplasia; case 3: benign prostatic
hyperplasia
Case 1: cystitis and bacteraemia; case 2:
cystitis; case 3: cystitis
Cases 1 and 2 had the same antibiogram:
resistant to ampicillin, cefuroxime,
piperacillin/tazobactam, mecillinam,
gentamicin; susceptible to ciproﬂoxacin
and TMP/SMX. Antibiogram not
performed for case 3
Case 1: initially started on piperacillin/
tazobactam, ciproﬂoxacin and discharged
after 6 days with oral ciproﬂoxacin; case
2: did not receive antibiotic treatment;
case 3: empiric treatment with
trimethoprim for 10 days. All patients
recovered
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